|
Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15. PubMed PMID: 28903342; PubMed Central PMCID: PMC5589581.
AÑO: 2017; IF: 5.168
|
28903342
|
Chen-Liang TH, Martín-Santos T, Jerez A, Rodríguez-García G, Senent L, Martínez-Millán C, Muiña B, Orero M, Teruel A, Martín A, Gómez-Espuch J, Kennedy K, Benet C, Raya JM, Fernández-González M, de la Cruz F, Guinot M, Villegas C, Ballester I, Baile M, Moya M, López-Jiménez J, Frutos L, Navarro JL, Uña J, Fernández-López R, Igua C, Contreras J, Sánchez-Vañó R, Cozar MDP, Tamayo P, Mucientes J, Sánchez-Blanco JJ, Pérez-Ceballos E, Ortuño FJ. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma. Cancer Med. 2017 Nov;6(11):2507-2514. doi: 10.1002/cam4.1205. Epub 2017 Sep 27. PubMed PMID: 28960797; PubMed Central PMCID: PMC5673915.
AÑO: 2017; IF: 3.202
|
|
Fernandez-Caballero M, Salmeron D, Dolores Chirlaque M, Chen-Liang TH, Hurtado AM, Garcia Malo MD, Ortuno FJ, Roldan V, Vicente V, Jerez A, De Arriba F. Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest. 2019 Feb;49(2):e13050. doi: 10.1111/eci.13050. Epub 2018 Dec 7. PubMed PMID: 30422316.
AÑO: 2019; IF: 3.481
|
|
Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumbreras E, Przychodzen B, Caparros E, Amigo ML, Dıez-Campelo M, Zamora L, Salido Fierrez EJ, Maciejewski JP, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marin F, Wiseman DH, Jerez A. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. Br J Haematol. 2018 Aug;182(3):373-383. doi: 10.1111/bjh.15408. Epub 2018 May 24. PubMed PMID: 29797327.
AÑO: 2018; IF: 8.615
|
|
Chen-Liang TH, Casado-Prieto AM, Campos-Rodríguez V, Hurtado AM, Amigo ML, García-Malo MD, Vicente V, Ortuño FJ, Jerez A. An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups. Int J Lab Hematol. 2018 May 18. doi: 10.1111/ijlh.12860. [Epub ahead of print] PubMed PMID: 29774987.
AÑO: 2018; IF: 2.073
|